Latest Blog Posts
Search
Sort Results
Filter by Topic
Filter by Infection
Filter by Resource Category
- Research summary (remove)
Search results
Current filters: Hepatitis C drugs, Treatment, Research summary, Maviret
8 search results
- FDA—Rare cases of liver injury with some hepatitis C treatments
-
2019, CATIE
Research summary - Webpage - Maviret for people with HCV and chronic kidney disease
-
From TreatmentUpdate 227
2018, CATIE
Research summary - Webpage - Experience with Maviret in northern Italy
-
From TreatmentUpdate 227
2018, CATIE
Research summary - Webpage - Germany—experience with Maviret after licensure
-
From TreatmentUpdate 227
2018, CATIE
Research summary - Webpage - Glecaprevir + pibrentasvir (Maviret)—highly effective against genotype 3
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage - Safety and efficacy of glecaprevir + pibrentasvir (Maviret) in cases of liver or kidney transplant with chronic HCV infection
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage - Glecaprevir + pibrentasvir (Maviret) in HCV genotype 1 or 4 with previous treatment failure
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage - New treatments for hepatitis C virus (HCV) to get approved in Canada later this year
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage
